Healthcare Contract Research Outsourcing Market share globally was worth USD 73.11 billion in 2024 and is anticipated to grow ...

YEMASSEE, SC / ACCESS Newswire / May 8, 2025 / Dr. Greg Westergaard, CEO of Alpha Genesis Incorporated (AGI), today ...

Funding Fuels National Sales Expansion and Launch of New Ortho EDG Sizes to Broaden Surgical Applications and Meet Rising ...

Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16Icotrokinra continues to ...

The global sports drug testing market is set for substantial expansion, with projections indicating a rise from USD 13.4 billion in 2022 to an impressive USD 20.6 billion by 2032. This represents a ...

Financial Results and Highlights of Recent Company Progress~ AMT-130 granted Breakthrough Therapy designation by FDA ~~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues ...

NextCell CSO Lindsay Davies Honoured with Multiple New Leadership Roles Within European Cell Therapy Community Davies' expertise critical to translating NextCell’s lead MSC product, ProTrans, through ...

UK Healthcare M&A remains robust throughout Q1 as deals continue to flow in 2025Pharma and life sciences and healthcare IT saw a notable uptick in volumes in March. The UK Healthcare M&A sector has ...

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF) Research conducted in collaboration with IPF experts and the ...

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of MedicineResults support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in ...

Kelso Pharma builds for future growth with appointment of life sciences leader as Chief Operating OfficerKelso Pharma, the growing UK-based specialty pharmaceuticals business, has appointed life ...

Vesper Bio achieves enrolment milestone in Phase Ib/IIa trial of lead candidate VES001 for frontotemporal dementia Phase Ib/IIa trial is to evaluate the efficacy of VES001 in asymptomatic patients ...